We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
This Mum Runs (TMR) aims to get more women running. They currently have a 4,000 person strong community, nearly 3,000 mums running and over 30% of those are paying for TMR's courses. This Mum Runs offer over 50 runs a month in Bristol and Bath alone and are looking to expand to other cities by the end of the year. 
days to go: Expired investment: £103,230
One Woman Driver is an online market place that allows consumers to buy used cars formally owned by women drivers.  The investment will be used to fund fast growth and a mobile app. (EIS Pending and SEIS Pending)
days to go: Expired investment: £416,770
Trippki is a live and operational hotel booking platform with more than 1.6m hotels around the world. The platform accepts payment in cryptocurrency for a growing crypto community who want to grow the ecosystem. The company caters to both the new traveller and the experienced traveller for offering a user-friendly hotel booking portal where users have access to hotels globally at competitive prices through Trippki.com. The company's standard booking platform is 'The Trippki Travel Club' where users become exclusive members to get access to discounts up to 60% off the public price. 45% of the proceeds will be used on towards the company's marketing and sales campaign to drive users to the hotel booking platform, 35% for team building and the rest of the 20% for the development of the platform.

Pitch Rated

79%

Gold

rating powered by

CROWD RATING™

days to go: Expired investment: £40,220
A new form of electric transport in the bike industry with the use of an affordable and simple conversion kit. Swytch have developed a kinetically rechargeable add-on for existing bikes to convert them into eBikes for a range of up to 50 miles. Funding will result in additional units being manufactured and sold at a 70% margin. The products are available online and currently via 20 independent bike dealers, with over 100 more waiting on stock.
days to go: Expired investment: £349,356
The Studio enable members to achieve results through sustainable, structured training. The Studio offer a whole range of sessions such as group classes, one-to-one personal training, spinning and yoga.   
days to go: Expired investment: £30,564
The Nice One App is an on-demand mobile app for van and recovery drivers. A user simply goes on the app, chooses where they want to be picked up from, what size van/recovery truck they need and then their request is sent out to the nearest available driver.
days to go: Expired investment: £65,090
DNApal is a personalised diet, health and fitness app that combines DNA infomation with other factors like age, weight, diet, family history and health goals. Two of the largest consumer DNA companies, 23andMe and Ancestry.com, have tested over 18m people. DNApal is capable of interpreting DNA results from these companies to provide precise recommendations on how to improve diet, hormone balance, weight loss, sleep, fitness & more. The company also won the best pitch at VentureFest 2019 at Oxford Brookes University. DNApal is aiming to launch MVP in January 2020 (iOS). The company is also aiming to recommend further testing and specific supplements where necessary and offer 1:1 consultations with a specialist. With the fund raised, DNApal plans to develop the full scope of the app, weekly goals, content challenges to keep users committed.

Pitch Rated

70%

Overall

rating powered by

CROWD RATING™

days to go: Expired investment: £49,990
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph